Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 11, 2021updated 12 Feb 2021 6:27am

BenevolentAI doses first patient in atopic dermatitis drug trial

UK-based BenevolentAI has dosed the first patient in its first-in-human clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).

UK-based BenevolentAI has dosed the first patient in its first-in-human clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).

Designed and developed using BenevolentAI’s scientific and technical expertise, BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery.

It has a pharmacokinetic profile designed for low systemic exposure to offer the optimal safety and efficacy profile in treating itch and inflammation linked to AD.

AD is characterised as a chronic relapsing inflammatory skin condition, which manifests as itchy, inflamed skin.

Estimates show that mild to moderate AD affects about 70% of all patients, with its occurrence rising globally.

BenevolentAI noted that the drug will be studied in adult subjects with mild to moderate AD in this initial trial.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

At present, the standard of care for the topical treatment of atopic dermatitis includes corticosteroids and calcineurin inhibitors which have usage limitations as well as adverse side effects.

There exists a huge unmet need for patients that are either non-responders or refractory to presently available treatments.

The company noted that BEN-2293 can potentially address both the inflammation and itch linked to AD in adults and children, indicating a comprehensive, new treatment available for a wider patient population.

BenevolentAI chief scientific officer Anne Phelan said: “The poor treatment options available for atopic dermatitis patients make the disease difficult to endure.

“New ways to treat this disease are desperately needed, and we believe our molecule has strong potential to address this serious unmet need without the use of topical steroids.

“The BEN-2293 trial also marks an important first step in the development of our in-house drug pipeline, and we are excited to be progressing this candidate into the clinic.”

The company has active R&D drug programmes in disease areas including ALS, ulcerative colitis and Oncology and research and commercial partnerships with AstraZeneca and Novartis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU